These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 17367093

  • 1. A randomized, open-label, multicenter trial comparing once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: improved physical functioning in the ACTION trial.
    Rauck RL, Bookbinder SA, Bunker TR, Alftine CD, Gershon S, de Jong E, Negro-Vilar A, Ghalie R.
    J Opioid Manag; 2007; 3(1):35-43. PubMed ID: 17367093
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain.
    Nicholson B, Ross E, Sasaki J, Weil A.
    Curr Med Res Opin; 2006 Aug; 22(8):1503-14. PubMed ID: 16870075
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain.
    Weil AJ, Masters ET, Barsdorf AI, Bass A, Pixton G, Wilson JG, Wolfram G.
    Health Qual Life Outcomes; 2017 Oct 17; 15(1):202. PubMed ID: 29041942
    [Abstract] [Full Text] [Related]

  • 7. Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial.
    Buynak R, Rappaport SA, Rod K, Arsenault P, Heisig F, Rauschkolb C, Etropolski M.
    Clin Ther; 2015 Nov 01; 37(11):2420-38. PubMed ID: 26428249
    [Abstract] [Full Text] [Related]

  • 8. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
    Binsfeld H, Szczepanski L, Waechter S, Richarz U, Sabatowski R.
    Pain Pract; 2010 Nov 01; 10(5):404-15. PubMed ID: 20384968
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A study of AVINZA (morphine sulfate extended-release capsules) for chronic moderate-to-severe noncancer pain conducted under real-world treatment conditions--the ACCPT Study.
    Adams EH, Chwiecko P, Ace-Wagoner Y, Mangefrida B, Duerden ME, Perdikis GC, Kunkel FA, Ghalie R.
    Pain Pract; 2006 Dec 01; 6(4):254-64. PubMed ID: 17129306
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
    Hale ME, Dvergsten C, Gimbel J.
    J Pain; 2005 Jan 01; 6(1):21-8. PubMed ID: 15629415
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.
    Yu S, Shen W, Yu L, Hou Y, Han J, Richards HM.
    J Pain; 2014 Aug 01; 15(8):835-44. PubMed ID: 24846822
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study.
    Baron R, Likar R, Martin-Mola E, Blanco FJ, Kennes L, Müller M, Falke D, Steigerwald I.
    Pain Pract; 2016 Jun 01; 16(5):580-99. PubMed ID: 26095455
    [Abstract] [Full Text] [Related]

  • 14. Factors affecting dosing regimens of morphine sulfate extended-release (KADIAN) capsules.
    Weil AJ, Nicholson B, Sasaki J.
    J Opioid Manag; 2009 Jun 01; 5(1):39-45. PubMed ID: 19344047
    [Abstract] [Full Text] [Related]

  • 15. Sleep improves when patients with chronic OA pain are managed with morning dosing of once a day extended-release morphine sulfate (AVINZA): findings from a pilot study.
    Rosenthal M, Moore P, Groves E, Iwan T, Schlosser LG, Dziewanowska Z, Negro-Vilar A.
    J Opioid Manag; 2007 Jun 01; 3(3):145-54. PubMed ID: 18027540
    [Abstract] [Full Text] [Related]

  • 16. Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules.
    Nicholson B, Ross E, Weil A, Sasaki J, Sacks G.
    Curr Med Res Opin; 2006 Mar 01; 22(3):539-50. PubMed ID: 16574037
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
    Ueberall MA, Mueller-Schwefe GH.
    Curr Med Res Opin; 2015 Mar 01; 31(7):1413-29. PubMed ID: 25942606
    [Abstract] [Full Text] [Related]

  • 18. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials.
    Etropolski M, Kuperwasser B, Flügel M, Häufel T, Lange B, Rauschkolb C, Laschewski F.
    Adv Ther; 2014 Jun 01; 31(6):604-20. PubMed ID: 24985410
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain.
    Hale ME, Fleischmann R, Salzman R, Wild J, Iwan T, Swanton RE, Kaiko RF, Lacouture PG.
    Clin J Pain; 1999 Sep 01; 15(3):179-83. PubMed ID: 10524470
    [Abstract] [Full Text] [Related]

  • 20. Clinical evaluation of the first oxycodone once daily prolonged release tablet in moderate to severe chronic pain: a randomized, double-blind, multicenter, cross-over, non-inferiority study to investigate efficacy and safety in comparison with an established oxycodone twice daily prolonged release tablet.
    Lux EA, Janecki M, Maritz MA.
    Curr Med Res Opin; 2014 Nov 01; 30(11):2365-75. PubMed ID: 25050592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.